Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Fractyl Health, Inc. - Common Stock (NQ: GUTS ) 2.455 -0.035 (-1.41%) Streaming Delayed Price Updated: 12:49 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Fractyl Health, Inc. - Common Stock Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference September 24, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health to Participate in Upcoming September Investor Conferences September 03, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Reports Second Quarter 2024 Financial Results and Provides Business Updates August 14, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Announces Clinical Results from German Real-World Registry Showing Meaningful and Sustained Weight Loss for at Least One Year After a Single Revita® Endoscopic Procedure August 08, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health to Report Second Quarter 2024 Financial Results and Provide Business Updates on August 14, 2024 August 07, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Receives FDA Breakthrough Device Designation for Revita in Weight Maintenance for People with Obesity Who Discontinue GLP-1 Based Drugs July 30, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day June 25, 2024 Company will discuss recent corporate updates, including compelling preclinical data from Rejuva® pancreatic gene therapy platform, which was named top abstract at American Diabetes Association’s 84th... From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Announces Advancement in Weight Maintenance Pipeline and Business Updates June 24, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Presents New Preclinical Data on Sustained Weight Maintenance and Improved Body Composition from its Rejuva® Single-Administration GLP-1 Pancreatic Gene Therapy in President’s Select Oral Presentation at the American Diabetes Association’s June 23, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions May 29, 2024 Management to host in-person KOL event and webcast at ADA on Monday, June 24, 2024, at 7:00 a.m. ET From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024 May 20, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates May 13, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D) May 13, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health to Present at BofA Securities 2024 Health Care Conference May 08, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 2024 May 07, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting April 30, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes April 02, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update April 01, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs April 01, 2024 From Fractyl Health, Inc. Via GlobeNewswire UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity March 12, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity March 12, 2024 From Fractyl Health, Inc. Via GlobeNewswire Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials February 20, 2024 From Fractyl Health, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.